1Q21 Investor Update
Q1 DEVELOPMENTS:
TOBACCO AND CANNABIS FRANCHISES
Tobacco Franchise
Steadily raising the intensity and frequency of communications
to secure FDA Modified Risk Tobacco Product (MRTP)
designation of VLNⓇ across FDA, executive, congressional
and state leadership
I
I
Fully prepared for commercial launch of VLN® within 90 days
of receiving MRTP designation
Expanded VLNⓇ tobacco growing program to support
anticipated consumer demand
Manufacturing capabilities geared for a strong commercial
launch and growth; adding in-house test and measurement
capabilities lowers cost, increases speed
Willing to license reduced nicotine technology to facilitate a
nicotine cap proposal to significantly reduce the harm caused by
smoking
Hemp/Cannabis Franchise
Changing regulations driving market growth, capital investment
and increased need for competitive differentiation
I
▪ Advancing development of end-to-end upstream cannabinoid
value chain capabilities to create disruptive, valuable plant lines
▪ Key partnerships in place to accelerate commercialization
of next-gen hemp/cannabis plant lines and IP in as little
as two years from trait identification to viable plants
▪ Extended and expanded our exclusive partnership with
KeyGene to lock in long-term strategic advantage
and future development
22nd Century Group, Inc.
Advancing monetization for 2H 2021 from initial plants
and IP; readying next generation of plants lines for
prospective customers
DISRUPTING THE +$1.3 TRILLION GLOBAL TOBACCO, HEMP/CANNABIS MARKETS, AND
THIRD PLANT-BASED FRANCHISE (TO BE ANNOUNCED)
tView entire presentation